samedan logo

 
 
spacer
home > pmps > spring 2018 > supply network
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Supply Network

In an industry where the entire supply chain is faced with the regulatory requirement for serialisation and traceability, the solution needs large-scale integration and interoperability. For pharmaceutical businesses, the biggest challenge is how they orchestrate project implementation both internally and externally. In the Global Drug, Supply, Safety and Traceability report, just 48% of CMOs have integrated with a majority of brand owners, and just 41% of respondents stated that a high percentage of their internal packaging lines are ready for serialisation (1).

In every business, project leads must consider the overall complexity and scale of serialisation and traceability. They must understand and update internal processes and engage external partners before specifying and implementing a strategy and solution. While the pharma sector is well-versed at improving the performance of manufacturing and packing lines with new hardware and site-level systems, integrating with partners, each with their own policies and priorities, on the scale required by global serialisation and traceability is a completely new challenge. To complicate matters, the solution cannot be stationary – new products, partners, markets and regulations, customer requirements, and opportunities keep coming.

Managing all of these is hard work, but three core pillars of serialisation and traceability integration and interoperability in product supply networks can lead to success.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Pasi Kemppainen is the Principal Advisor on pharma digitalisation at Epista Life Science. He is currently leading Santen Pharmaceutical’s global serialisation and traceability programme. Prior to Epista Life Science, Pasi worked as Senior Consultant and Advisor for NNE – a Novo Nordisk engineering and consulting company. He also served as CEO at Original1 (a joint venture of SAP, Nokia, and Giesecke & Devrient – leaders in enterprise IT, mobile, and security), servicing a cloud and mobile platform for product serialisation, traceability, and consumer authentication services in Europe and China.
spacer
Pasi Kemppainen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Pistoia Alliance Launches Global Community of Interest to Assess the Environmental Impact of Clinical Trials


More info >>

White Papers

Recommendations Sourcing Human Biospecimens

BioIVT

The foundations for protecting human research subjects come from the ethical principles surrounding the Belmont report : Respect for persons, beneficence, and justice. The use of human biospecimens in research supports these principles with legal and ethical regulations - the most important of which is permission.(1) This permission may come directly from the donor or granted by others with authorization to protect the interests of biospecimen donors.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement